Nachrichten

bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel

04 Mai, 2022

Joint infections (“septic arthritis”) are serious infections involving either native  or prosthetic joints. They are medical emergencies which can occur at all ages, and can lead to functional joint impairment, long-lasting disability, and may even be life-threatening. The number of prosthetic...

z.B. 03/29/2024
z.B. 03/29/2024

bioMérieux receives CE Mark certification for IVD products marketed in the European Union

08 Januar, 2004

bioMérieux has received CE Mark certifications for all of its in vitro diagnostic (IVD) products currently marketed in the European Union (EU). In compliance with the requirements of the 98/79/EC directive for CE Marking, which became applicable on December 7th, 2003, these certifications enable bioMérieux to continue to sell its products within the European Union after this date.

Cepheid and bioMérieux enter into strategic commercial program

06 Januar, 2004

bioMerieux to Apply Cepheid Platform Technology to NASBA Amplification Technology.

Pioneering Diagnostics